SPG20 antibody (C-Term)
Quick Overview for SPG20 antibody (C-Term) (ABIN954907)
Target
See all SPG20 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 490-519, C-Term
-
Specificity
- This antibody recognizes Human
-
Purification
- Affinity Chromatography on Protein A
-
Immunogen
- KLH conjugated synthetic peptide between 490-519 amino acids from the C-terminal region of Human SPG20 Genename: SPG20
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS, 0.09 % Sodium Azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
-
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
-
Alternative Name
- Spartin / SPG20
-
Background
- SPG20 is a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome)Synonyms: KIAA0610, Spastic paraplegia 20 protein, TAHCCP1, Trans-activated by hepatitis C virus core protein 1
-
Molecular Weight
- 72833 Da
-
Gene ID
- 23111
-
NCBI Accession
- NP_001135766
-
Pathways
- Regulation of Cell Size, SARS-CoV-2 Protein Interactome
Target
-